Eupraxia Pharmaceuticals (NASDAQ:EPRX) released new 24-week results from the highest dose cohort of its Phase 1b/2a RESOLVE trial, evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
Monte Rosa Therapeutics (NASDAQ:GLUE) reported a net loss of $46.1 million for the fourth quarter ended December 31, 2025.
High Tide (NASDAQ:HITI) reported its financial results for the first fiscal quarter ended January 31, 2026, marking its strongest start to a fiscal year to date.
Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology firm pioneering "Bicycle" peptide technology, reported its fourth-quarter and full-year 2025 financial results on March 17, 2026.
Gyre Therapeutics (NASDAQ:GYRE) reached a critical regulatory milestone as the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Priority Review status to the New Drug Application (NDA) for Hydronidone (F351).
Kalaris (NASDAQ:KLRS) reported its fourth-quarter and full-year 2025 financial results today, delivering a clinical update that positions its lead candidate as a potential disruptor in the $13 billion anti-VEGF market.
IceCure Medical (NASDAQ:ICCM) announced record financial results for the fourth quarter and full year ended December 31, 2025, marking a transformative period for the Israeli medtech firm.
Neuronetics (NASDAQ:STIM), the leader in Transcranial Magnetic Stimulation (TMS) therapy for mental health, reported its fourth-quarter and full-year 2025 financial results, reflecting the transformative impact of its late-2024 acquisition of Greenbrook TMS.
CervoMed (NASDAQ:CRVO) announced on Tuesday that it has achieved critical regulatory and clinical alignment for the Phase 3 development of neflamapimod, its oral small-molecule treatment for dementia with Lewy bodies (DLB).
Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
X4 Pharmaceuticals (NASDAQ:XFOR) reported its fourth-quarter and full-year 2025 financial results on March 17, 2026, marking a year of transition from a clinical-stage entity to a commercial-revenue-generating firm.
Pfizer (NYSE:PFE) reported a significant clinical milestone in its oncology pipeline today, announcing that the Phase 2 FOURLIGHT-1 study of atirmociclib met its primary endpoint.
